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The in vitro activity of six cathelicidin peptides against the reference strain Z of Simkania negevensis was investigated. Five
peptides—PG-1, Bac7, SMAP-29, BMAP-27, and BMAP-28—proved to be active at very low concentrations (1 to 0.1µg/mL),
while LL-37 cathelicidin was ineﬀective even at a concentration of 100µg/mL. In comparison to chlamydiae, S. negevensis proved
to be more susceptible to the antimicrobial peptides tested.
1.Introduction
Simkania negevensis is an obligate intracellular Gram-nega-
tive bacterium belonging to the family of Simkaniaceae in
the order Chlamydiales [1], discovered as a contaminant in a
variety of cell cultures [2], and is able to grow also in various
environmental free-living amoebae such as Acanthamoeba
poliphaga [3].
Epidemiologic studies have reported a human widesp-
read exposure to this bacterium [4, 5], both in healthy sub-
jects and in association with respiratory diseases in infants
and adults [6–10]. Coinfections with other pathogens have
beendescribed,suchasrespiratorysyncytialvirusinchildren
and inﬂuenza virusand other bacterialspecies in adults[7,8,
11]. A possible association between S. negevensis and acute
rejection in lung transplant recipients has been suggested
[12]. S. negevensis DNA has also been ampliﬁed from an
aortic aneurysm [13, 14].
PreviousinvestigationsreportedS.negevensisinvitrosus-
ceptibility to azithromycin, minocycline, erithromycin, dox-
ycycline, and oﬂoxacin like chlamydiae [15] and the lack
of susceptibility to ampicillin, penicillin G, bacitracin, cycl-
osporine, and ﬂuoroquinolones [2, 15, 16].
S e v e r a ls t u d i e s[ 17–20] demonstrated the in vitro antich-
lamydial activity of peptides, such as cathelicidins, stored by
mammalian leucocytes and show an antimicrobial activity
against bacteria, fungi, protozoa, and enveloped viruses.
With regard to the mode of action of these peptides against
chlamydiae, previous investigations on the activity of prote-
grins [21] suggested an initial binding to lipopolysaccharide
followed by insertion into the membrane that results in
permeabilization. Yasin et al. [22] demonstrated that the
antichlamydial activity of protegrins resided especially in
residues 5 to 15 of native protegrin-1 and required both
intramolecular disulﬁde bonds.
In the present study, we investigate the in vitro activity of
six antimicrobial peptides against the reference strain Z of S.
negevensis.
2.MaterialsandMethods
Thecathelicidinpeptides—PG-1frompig,Bac7(1–35)from
cattle, SMAP-29 from sheep, LL-37 from human, BMAP-
27, and BMAP-28 from cattle—were chemically synthesized,
puriﬁed, characterized, and provided as lyophilized peptide,
as previously reported [19]. The reference strain Z of S.
negevensis (American Type Culture Collection VR-1471) was
grown in LLC-MK2 cells [23] in 6-large well plates and
elementary bodies (EBs) were puriﬁed by use of sucrose
gradients [24], resuspended in sucrose-phosphate-glutamic2 International Journal of Peptides
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Figure 1: Activity of cathelicidin peptides at diﬀerent concentrations on the infectivity of Simkania negevensis.
acid buﬀer (SPG) pH 7.4 (75g sucrose, 87mL 0.2M
Na2HPO4, 13mL 0.2M NaH2PO4, 0.72g L-glutamic acid),
a n df r o z e ni na l i q u o t sa t−80◦C.
Stock solutions of each peptide at 1g/liter were prepared
in phosphate-buﬀered saline (PBS), pH 7.4, and stored
frozen in 20-µL aliquots at −80◦C until used. To determine
the lowest peptide concentration required to achieve ≥50%
reduction of inclusions with respect to untreated control,
the various peptides were diluted tenfold from 200 to
0.02µg/mL,inavolumeof100µLwithPBSinpolypropylene
tubes. An equal volume of 5 × 105 inclusion-forming units
(IFU)/mL of puriﬁed S. negevensis EBs in SPG medium was
then added, so obtaining a ﬁnal cathelicidin concentration
ranging from 100 to 0.01µg/mL in a mixture of PBS and
SPG at a ﬁnal pH 7.4. EBs untreated with cathelicidins were
used as a control. After incubation at room temperature for
2h, a 200µL aliquot was added to 800µL chlamydial growth
medium and inoculated onto LLC-MK2 cells grown in 24-
well plates in a 5% CO2 atmosphere. After centrifugation at
800×gf o r1ha t3 3 ◦C and incubation at 35◦C for 72h, the
cultures were ﬁxed and stained for the presence of inclusions
by immunoﬂuorescence using an in-house rabbit polyclonal
hyperimmune serum raised against S. negevensis.T h en u m -
ber of IFU per coverslip was counted in 40 microscopic ﬁelds
using a ZEISS UV microscope at a magniﬁcation of ×200.
All tests were performed in triplicate and in three
independent experiments.
3. Results andDiscussion
The activities of the six cathelicidin peptides against S.
negevensis are reported in Figure 1 and are the means of
results from the three experiments. In comparison with the
infectivity of the untreated control (mean value 74 IFU/mL),
Bac7 and SMAP-29 reduced by >50% (<37IFU/mL) the
inclusion numbers of S. negevensis at a concentration of
0.1µg/mL, whereas PG-1, BMAP-27 and BMAP-28 showed
the same activity at a concentration of 1µg/mL. All these
ﬁve cathelicidins demonstrated a very slow decrease in their
inhibitory eﬀect while their concentration has been reducing
from 100 to 1 or 0.1µg/mL. LL-37 peptide did not exert any
inhibitory eﬀect, even at a concentration of 100µg/mL.
In our previous study [19], the activity of six cathelici-
dins—PG-1, Bac7, SMAP-29, BMAP-27, LL-37 and BMAP-
28—tested on chlamydiae of human and animal origin
showed that ﬁve of them had inhibitory eﬀect on Chlamydia
trachomatis strains, SMAP-29 being the most active peptide
at a concentration of 10µg/mL; on the contrary, LL-37
peptide was ineﬀective even at a concentration of 80µg/mL.
With regard to the other chlamydial species tested, only
Chlamydophila pneumoniae and Chlamydophila felis were
sensitive to 10µg/mL of SMAP-29 and 80µg/mL of SMAP-
29/Bac7, respectively.
In the present investigation, the same six cathelicidins
were tested against the reference strain Z of S. negevensis.I n
comparison with chlamydiae, S. negevensis was not sensitive
to LL-37 even at the concentration of 80µg/mL, but very
sensitive to all the other ﬁve cathelicidins that showed
an inhibitory eﬀect at very low concentrations from 1 to
0.1µg/mL. To our knowledge no study on S. negevensis
susceptibility to cathelicidins has been performed, until
now. These preliminary results suggest a higher sensitivity
of S. negevensis to cathelicidins respect to chlamydiae. A
previous study showed diﬀerences in the susceptibility of
diﬀerent C. trachomatis serovars to antimicrobial peptides,
suggesting that limited variations in the disulﬁde bonding in
the membrane structure of these organisms may inﬂuence
theirsusceptibilitytopeptides[18].Themembranestructure
of S. negevensis probably diﬀers signiﬁcantly from that of
other members of Chlamydiales, as monoclonal antibodies
recognizing family-speciﬁc epitopes of chlamydial OMP-2,
MOMP, and LPS did not bind S. negevensis antigens [2, 25];
in addition, only a relatively small number of common
epitopes were shown to be shared when S. negevensis and
other Chlamydiales members were tested for cross-reactivity
by Western blot using polyclonal antisera [26]. The higherInternational Journal of Peptides 3
susceptibility of S. negevensis to cathelicidins in comparison
to chlamydiae could be referred, to a great extent, to its
diﬀerent polypeptides pattern.
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